User:Mr. Ibrahem/Erdafitinib

Erdafitinib, sold under the brand name Balversa, is a medication used to treat urothelial cancer. Specifically it is used for cases which have suitable FGFR-2 or 3 mutations. It is taken by mouth.

Common side effects include high phosphate, mouth inflammation, tiredness, kidney problems, diarrhea, liver problems, change in taste, low magnesium, hair loss, high calcium, and muscle pain. Other side effects may include infertility and vision problems. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor, specifically a fibroblast growth factor receptor (FGFR) blocker.

Erdafitinib was approved for medical use in the United States in 2019. It is not approved for use in the United Kingdom or Europe as of 2021. In the United States 4 weeks of treatment costs about 21,500 USD as of 2021.